Large Cap

Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss, an improvement from a loss of $3.33 a year ago. The COVID-19 vaccine maker reported quarterly sales of $142 million, beating the consensus of $116.34 million...

Editor’s Note: The story has been updated with statement from Roblox Roblox Corporation (NYSE:RBLX) shares are falling after news broke of a new lawsuit seeking to hold the gaming platform and Discord accountable for allegedly enabling the sexual exploitation of a minor. The suit,...

The biotechnology sector is witnessing a surge in investor optimism as companies like Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) continue to outperform market expectations. Amid a backdrop of growing demand for innovative treatments, Alnylam’s recent performance highlights the company’s...

Baxter International Inc. (NYSE:BAX) is down 19.4% at $22.66 at the last check on Thursday. At around 11 a.m. EST, shares of the medical device company traded at $21.68—just shy of its 52-week low. Baxter reported a second-quarter adjusted EPS of 59 cents. That’s inline with the management...

A post-earnings surge in Meta Platforms Inc. (NASDAQ:META) and Microsoft Corp. (NYSE:MSFT) sent major tech-heavy indices to fresh record highs Thursday, capping a fourth consecutive month of gains for U.S. equities. By midday in New York, the S&P 500 rose 0.7% to break above 6,400, while the...

U.S. stocks just wrapped up another strong month of gains with record-breaking levels, but history warns that August could quickly flip the script on this summer rally. The MAGS ETF is trading at new record highs. See the chart here. The S&P 500, tracked by the Vanguard S&P 500 ETF (NYSE:...

Cigna Group (NYSE:CI) reported second-quarter 2025 revenue of $67.13 billion on Thursday, beating analyst estimates of $62.46 billion. Sales increased 11% year over year, primarily driven by Evernorth Health Services, and include growth of existing client relationships and strong specialty...

Carvana Co (NYSE:CVNA) shares rallied in early trading on Thursday, after the company reported on Wednesday positive second-quarter earnings. CVNA shares are getting near their 52-week high. Check the latest price here. The announcement came amid an exciting earnings season. Here are some key...

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% year over year, beating the analyst consensus of $4.06. The company reported sales of $2.65 billion, up 7% year over year on a reported basis, 8% on constant...

AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion. Sales increased 6.6% on a reported basis or 6.5% on an operational basis. The company reported adjusted earnings of $2.97, up 12.1% year over year and missing the...

Wall Street's most powerful tech giants are rewriting the rules of market dominance. What Happened: The so-called Magnificent Seven tech giants surged to a record-breaking $19.4 trillion in combined market value Thursday morning. This latest surge is reshaping the very structure of the S&P 500—...

Bristol Myers Squibb & Co (NYSE:BMY) reported second-quarter 2025 revenues of $12.27 billion, beating the consensus of $11.31 billion, almost flat year over year. U.S. sales slipped 3% to $8.5 billion, while international revenues climbed 10% to $3.8 billion, representing an 8% increase...

CVS Health Corp (NYSE:CVS) stock is trading higher on Thursday after the company reported better-than-expected Q2 earnings and raised its annual guidance. The company reported second-quarter sales of $98.90 billion on Thursday, beating the consensus of $94.85 billion. Total revenues increased...

Sanofi SA (NASDAQ:SNY) reported second-quarter sales of $11.33 billion (€9.99 billion euros), narrowly missing the consensus of $11.53 billion. Sales increased 6% year over year, up 10.1% in constant currency, driven by growth in Immunology, pharmaceutical launches and Beyfortus. The French drug...

Eli Lilly and Co. (NYSE:LLY) released topline results from SURPASS-CVOT, a head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, to Trulicity (dulaglutide), a GLP-1 receptor agonist. In SURPASS-CVOT, Mounjaro achieved the primary...